Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 11th February 2021
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vetoquinol acquires Canadian rights to Profender®
"The acquisition of this strong brand for the Canadian market confirms our ambition to become a major player in the parasiticide segment" - Matthieu Frenchin, CEO of Vetoquinol.
Product family encompasses a range of spot-on solutions for cats

Animal health company Vetoquinol has announced the acquisition of the Canadian rights to the Profender® product family from Elanco Animal Health.

The move follows the firm's acquisition of Profender® and Drontal® product families, in relation to Elanco's 2020 acquisition of Bayer Animal Health. In January 2021, Vetoquinol also acquired the Profender® and Drontal® product families in Australia.

Commenting on the acquisition, Matthieu Frechin, CEO of Vetoquinol, said: "We are very pleased to acquire Profender® for the Canadian market, one of our prominent strategic countries. 

“The acquisition of this strong brand for the Canadian market confirms our ambition to become a major player in the parasiticide segment. Adding this essential to our product portfolio in Canada will strengthen our market share in the pet segment in this strategic country.” 

The Profender® family of products encompasses a range of spot-on solutions for cats.

 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.